Dysregulated FDX1 in ccRCC could promote tumor progression through metabolic reprogramming and carcinogenic pathways, such as fatty acid metabolism, PI3K-AKT-mTOR signaling, and the Myc pathway. This evidence concerns the gene AKT1 and nonpapillary renal cell carcinoma.